Why the study?
Does continuous monitoring with an insertable cardiac monitor improve atrial fibrillation detection compared to simulated intermittent monitoring in patients with cryptogenic stroke?
Does continuous monitoring with an insertable cardiac monitor improve atrial fibrillation detection compared to simulated intermittent monitoring in patients with cryptogenic stroke?
Continuous monitoring with an insertable cardiac monitor detects atrial fibrillation in approximately 1 in 5 cryptogenic stroke patients at 2 years, significantly outperforming conventional intermittent monitoring strategies in a real-world setting.
Supports continuous monitoring for cryptogenic stroke to maximize AF detection; extends prior trial.
BACKGROUND: The long-term incidence of atrial fibrillation (AF) in cryptogenic stroke (CS) patients has been explored in carefully controlled clinical trials but real-world data are limited. We investigated the two-year incidence of AF in real-world clinical practice among a large cohort of patients with an insertable cardiac monitor (ICM) placed for AF detection following CS. METHODS: Patients in the de-identified Medtronic Discovery™ Link database who received an ICM (Reveal LINQ™) for the purpose of AF detection following CS were included and monitored for up to 2years. All detected AF episodes (≥2min) were adjudicated. We quantified the AF detection rate using Kaplan-Meier survival estimates, analyzed the median time to initial detection of AF, and simulated the ability of various intermittent monitoring strategies to detect AF. RESULTS: A total of 1247 patients (65.3±13.0years, 53% male) were included and followed for 579±222days. AF episodes (n=4183) were detected in 238 patients, resulting in an AF detection rate of 21.5% at 2years. The median time to AF detection was 112 [IQR 35-293] days. Intermittent monitoring for AF detection was inferior to continuous ICM monitoring with sensitivities ranging from 2.9% (annual 24-hour Holter) to 29.9% (quarterly 7-day Holters), p<0.001. CONCLUSIONS: AF episodes were detected via continuous monitoring with ICMs in approximately 1 of every 5 CS patients within 2years of follow-up. The vast majority of patients with AF would not have been detected with conventional external ambulatory monitors. ICMs should therefore be considered in the evaluation of CS patients.
No takes yet. Share an insight, caveat, or question.
Ziegler et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: